Glucokinase Activator and Biguanide Fixed-Dose Combination for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral hypoglycemic drugs for diabetes primarily target single glucose-controlling organs, failing to effectively manage imbalanced blood glucose homeostasis, especially when used alone or after a period of treatment.
Innovation Solution
A pharmaceutical combination and fixed dose combination formulation comprising a glucokinase activator, such as HMS5552, in combination with a biguanide hypoglycemic drug like metformin hydrochloride, optimized for simultaneous release and enhanced bioavailability, to improve glucose regulation and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oral hypoglycemic drugs target single glucose-controlling organs, then the drug mechanism is simple and easy to manufacture, but the effectiveness in managing imbalanced blood glucose homeostasis is insufficient
Solution Approach 1:
The patent combines multiple hypoglycemic drugs with different mechanisms of action (glucokinase activator, biguanide, DPP-4 inhibitor, SGLT2 inhibitor) into a single fixed-dose combination formulation. This merging approach allows simultaneous targeting of multiple glucose-controlling organs and pathways, thereby improving the reliability of blood glucose homeostasis management while addressing the limitations of single-drug therapies.
Solution Approach 2:
The fixed-dose combination formulation serves multiple functions: it activates glucokinase, inhibits gluconeogenesis, enhances insulin secretion, and promotes glucose excretion. This multi-functional approach enables a single formulation to address various aspects of diabetes pathophysiology, improving overall effectiveness without requiring multiple separate medications.
2Reliability
If multiple drugs are used to improve glucose control in multiple organs, then the therapeutic effectiveness increases, but the number of pills and total drug dose increases
Solution Approach 1:
The patent merges multiple individual drug formulations into a single fixed-dose combination tablet containing predetermined amounts of each active ingredient. This consolidation reduces the number of pills patients need to take from multiple separate tablets to just one, while maintaining the therapeutic effectiveness of all components.
Solution Approach 2:
The single fixed-dose combination formulation provides multi-functional therapeutic effects by incorporating drugs that act through different mechanisms. This allows one pill to replace multiple pills, reducing the total quantity of substances patients need to ingest while achieving comprehensive glucose control.
3Reliability
If glucokinase activator is used alone, then the mechanism is simple, but the hypoglycemic effect is insufficient compared to combination therapy
Solution Approach 1:
The patent combines glucokinase activator with other hypoglycemic drugs having complementary mechanisms of action. This combination creates a synergistic effect where the glucokinase activator enhances insulin secretion while the partner drugs address insulin resistance and glucose production, together producing a stronger hypoglycemic effect than any single agent alone.
Solution Approach 2:
The fixed-dose combination formulation acts as a composite therapeutic material integrating multiple pharmacological agents. Each component contributes its unique mechanism of action, and their composite effect produces superior hypoglycemic control compared to individual drugs, justifying the increased formulation complexity.
Data Source
AI summary
A pharmaceutical combination. The pharmaceutical combination contains a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic marker thereof, a crystalline form thereof, a hydrate, a solvate, a diastereoisomer or an enantiomer form, and a biguanide hypoglycemic drug. A pharmaceutical composition and a fixed dose combination preparation as well as a preparation method and use of the pharmaceutical composition and the fixed dose combination preparation.